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Heterogeneity and clinical realityMany clinical researchers tend to perceive heterogeneity
as a burden one should control for by sophisticated statisti-
cal approaches, or even get rid of by averaging out or exclu-
sion. At the same time however, it is increasingly realized
that clinical reality is heterogeneous rather than homoge-
neous [1,2]. The complexities resulting from this insight
must be accepted to make sure that clinical research, and
the efforts and investments put into it, yields maximal clin-
ical impact and can effectively deal with both similarities
and differences between patients, settings, and clinicians
[3,4]. By the same token, we must comprehensively com-
pare the effects of various interventions that compete for
the same clinical indication, not only to check whether
one of these is overall superior, but also to find out if differ-
ent patient subgroups may be better off with different inter-
ventions. The challenge is finding the best balance between
simplicity and complexity, according to the famous words
of Albert Einstein, ‘‘Make everything as simple as possible,
but not simpler.’’ These words should also be kept in mind
while moving forward with individualized or personalized
medicine.
Addressing complexity adequately can even make things
less complex and challenging for patients, doctors, payers,
and regulators. In a Commentary, Naci and O’Connor em-
phasize the importance of assessing comparative effective-
ness [5] of new drugs before approval, using prospective
network meta-analyses. They demonstrate how their pro-
posed approach may help to improve health care and policy
decisions. Also, future research can be facilitated as to sam-
ple size estimation and identifying treatment effect modi-
fiers for further exploring heterogeneity.
Varadhan et al. contribute to the debate on how to appro-
priately deal with individuals varying in their response to
treatment, regarding both beneficial and adverse effects.
These authors underline that heterogeneity of treatment is
central to patient outcomes research, and consider the cur-
rent view of heterogeneity of treatment effect too limited.
They propose an expanded framework for the assessment
of heterogeneity of treatment effects.
In this context, the many advantages that individual
participant data (IPD) meta-analysis offers compared with
the meta-analysis of aggregate data should not be over-
looked. Among those advantages, described by Abo-Zaid
and co-authors, is better dealing with study heterogeneity
and subgroup effects. But as the authors show, using both
real and simulated examples, in such studies individual0895-4356  2013 Elsevier Inc.
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one single study. Researchers must routinely account for
the clustering of patients within different studies to avoid
misleading effect estimates and inappropriate clinical
conclusions.
Acknowledging heterogeneity as part of clinical reality
and integrating this insight in clinical research does not
make comparability of patient outcome less important.
On the contrary, such comparability is essential for system-
atically reviewing what interventions serve patients best.
Sautenet et al. compared registered protocols of clinical tri-
als in nephrology with such protocols in rheumatology, in
which guidelines for standardized outcome measures have
been accepted for a long time [6]. They found that reporting
and homogeneity of outcomes are better in rheumatology
than nephrology protocols, and encourage the establish-
ment of OMERACT-like approaches also for nephrology
and other medical fields.
To optimally account for individual variation in the bur-
dens suffered by patients, progress in designing and im-
proving outcome measures is asking ongoing attention, as
is shown by Busija and her team. In a review of thousands
of publications on self-report measures of osteoarthritis,
they identified not less than 158 multi-item measures. De-
spite this, they found that many aspects of the burden of os-
teoarthritis are not well represented by currently available
measures. But the comprehensive list of measures provided
in this review can help researchers in preparing the best se-
lection of measures for their purpose.
In studying the development of patient outcome over
time, an intriguing question is whether it is valid to com-
bine follow-up and change data in meta-analyses of contin-
uous outcomes. This was evaluated for osteoarthritis in
a meta-epidemiological study by da Costa et al. of meta-
analyses of trials including a total of almost 300 random-
ized comparisons. The authors concluded that combining
follow-up and change data is generally valid, but the deci-
sion of which type of data to use should be pre-specified in
the meta-analysis protocol.
An even broader concept than patient outcome is patient
experience, especially in relation to chronic disease. Based
on an interpretative synthesis of the research literature,
Morrow and her group identified and examined mecha-
nisms through which the experiences of chronic patients
can be accessed and used to improve health care, health
outcomes, quality of life, and many other aspects that are
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needs for further research.
While the Journal of Clinical Epidemiology publishes
many papers on the methodology of systematic reviews
and meta-analysis of the effects of interventions, to date
there has not been provided clear guidance for the review
of implementation of interventions in trials. Therefore,
based on a systematic literature search and consensus de-
velopment among systematic reviewers, Montgomery and
co-authors present a new tool to help systematic reviewers
to extract and compare implementation data across trials:
the Oxford Implementation Index, which can be also useful
for critical appraisal by clinicians and for better reporting
by trialists. The index is a work in progress and will be fur-
ther refined.
As Fretheim and colleagues emphasize, little is known
about the relative validity of randomized and non-
randomized approaches to evaluate the effectiveness of
health system interventions. Therefore, using data from
a cluster-randomized trial on a quality improvement inter-
vention for prescribing antihypertensive medication, they
compared the results of the actually conducted trial with
the results of an interrupted time-series (ITS) analysis.
The latter approach yielded an effect estimate concordant
with the effectiveness of the trial. Evidence from a broader
range of comparisons from other trials would help to eval-
uate the generalizability of this result.
Obtaining sufficient and valid data is always a primary
concern of clinical researchers. As in longitudinal studies,
attrition can lead to imprecise and biased results, David
et al. compared the performance of four models in analyz-
ing attrition risk using data from a follow-up study on skin
cancer. According to the authors, risk of attrition may be
better analyzed using an approach that allows for the incor-
poration of time-to-event data and time-varying covariates,
such as survival analysis, as opposed to logistic modeling.
But prevention of high attrition rates and promoting com-
pliance and adherence should of course be the first step.
Therefore, it is useful to keep studying the effectiveness
of methods to better achieve this goal. Lannin and her
group compared the efficiency and costs of telephone-
and mail-based assessments of post-hospital outcome of pa-
tients registered in the Australian Stroke Clinical Registry.
The mail approach turned out to be slower, but it produced
a similar completion rate and was cheaper to conduct, so it
can be considered especially in a context of limited
resources.
Despite all methods to try and obtain an optimal amount
of data, it is sometimes impossible to achieve a sample size
meeting the usual requirements of generally accepted pairs
of maximum values of type I and type II errors. To better
deal with such situations, Ioannidis et al. demonstrated an
approach to model how to select the optimal pair of type
I and type II errors that maximize the study value given
a constrained sample size.Interviewer effects are a well-known problem in epide-
miologic research, and we should be especially keen on this
when dealing with sensitive issues such as abuse. Fraga and
co-workers studied this issue in the context of an interview-
based study to assess the (determinants of) occurrence of
elder abuse in a population-based sample. Although no
interviewer-related effect-modification was observed, there
was confounding of the association between abuse and
other sensitive topics.
Anxiety has been reported to be a risk factor not only for
complications and mortality and but also for slower return
to work in patients with cardiovascular disease. Therefore,
Abberger and colleagues developed and calibrated an Anx-
iety Item Bank for cardiovascular patients (AIB-cardio) as
a basis for a computer adaptive test (CAT) to be used in car-
diovascular rehabilitation patients. Using data from a large
group of inpatient rehabilitation patients, the investigators
concluded that the AIB-cardio provides a good basis for
a CAT to assess anxiety in this target group. They recom-
mend further testing in other patients with cardiovascular
disease.
A good example of how to further develop diagnostic re-
search from accuracy research toward other relevant as-
pects of appropriate clinical diagnosis is the study of
Macia et al. Using patient data from a large hospital cancer
registry, they found that differences between the interval
from clinical suspicion to treatment onset and the interval
from diagnostic certainty to treatment onset varied highly
by tumor site, stage, and mode of hospital admission. To fa-
cilitate better studying and decreasing therapeutic delay,
they recommend more standardized definitions and proce-
dures to calculate intervals between cancer diagnosis and
treatment onset.
There is still discussion on whether and how to score tri-
als as to their methodological quality. In a letter, Doi and
Barendregt comment on the article of Da Costa et al. [7],
who earlier criticized the use of summary quality scores
in meta-analysis.
Last but not least, because the Journal of Clinical Epide-
miology has a specific focus on research methodology, we
especially recommend the new 1-pager in the monthly se-
ries on effective writing and publishing scientific papers
by Kotz and Cals, this time dealing with the ‘methods’
section.
J. Andre Knottnerus
Peter Tugwell
Editors
E-mail address: anneke.germeraad@maastrichtuniversity.nl
(J.A. Knottnerus)References
[1] Gartlehner G, West SL, Mansfield AJ, Poole C, Tant E, Lux LJ, et al.
Clinical heterogeneity in systematic reviews and health technology
811Editorial / Journal of Clinical Epidemiology 66 (2013) 809e811assessments: synthesis of guidance documents and the literature. Int J
Technol Assess Health Care 2012;28:36e43.
[2] Ioannidis JP. Interpretation of tests of heterogeneity and bias in meta-
analysis. J Eval Clin Pract 2008;14:951e7.
[3] Knottnerus JA, Dinant GJ. Medicine based evidence, a prerequisite
for evidence based medicine. BMJ 1997;315:1109e10.
[4] Concato J. Is it time for medicine-based evidence? JAMA 2012;
307:1641e3.[5] Sox HC,HelfandM,Grimshaw J, Dickersin K, PLoSMedicine Editors,
ToveyD,Knottnerus JA,Tugwell P.Comparative effectiveness research:
challenges for medical journals. J Clin Epidemiol 2010;63:862e4.
[6] Boers M, Tugwell P. OMERACT conference questionnaire results:
OMERACT Committee. J Rheumatol 1993;20:552e4.
[7] da Costa BR, Hilfiker R, Egger M. PEDro’s bias: summary quality
scores should not be used in meta-analysis. J Clin Epidemiol 2013;
66:75e7.
